NUDT5 and acute lymphoblastic leukemia: In this study, we performed a NUDIX-targeted CRISPR/Cas9 screen in human B-ALL cells treated with thiopurine and found that NUDIX hydrolase 5–deficient cells were resistant to thiopurine.